ArticleAnnals of hematology2024

Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation.

Josephine Lucero et al.PubMed ↗Publisher ↗

No numbers read from the abstract.